Cassandra, Chicken Little, and Public Policy for Start-Ups
Executive Summary
Given the drastic investment situation for health care start-ups, it's time for some modest government rule changes: bring back tax-advantaged R&D partnerships; let biotechs and small device companies sell their net operating losses; set up clear rules for accounting for purchased R&D.